Your email has been successfully added to our mailing list.

×
0 0 0 0 0.00202429149797579 0.000337381916329337 0.000337381916329337 0.000337381916329337
Stock impact report

Merck Posts Another Advance In The Lucrative Lung Cancer Market [Seeking Alpha]

Merck & Company, Inc. (new) (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
Company Research Source: Seeking Alpha
Merck Posts Another Advance In The Lucrative Lung Cancer MarketSummaryMerck presents positive first-line NSCLC results at the AACR Annual Meeting 2018 conference.Keytruda in combination with chemo was able to reduce the rate of disease progression or death by 51% compared to chemo alone.The presented data for KEYNOTE-189 puts Merck ahead over Bristol-Myers Squibb in the first-line lung cancer market.Merck already has an FDA approved combo of Keytruda and chemo to treat first-line patients with first-line metastatic nonsquamous NSCLC. Show less Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MRK alerts
Opt-in for
MRK alerts

from News Quantified
Opt-in for
MRK alerts

from News Quantified